Month: April 2021

Le conseil d’administration de Vastned Retail Belgium a décidé de nommer définitivement Mr. Walta en tant que CEO stratégique à compter du 23 avril 2021. Mr. Walta a déjà occupé ce poste de CEO stratégique ad interim à partirdu 1er décembre 2020. Communiqué de press complet: Pièce jointePersbericht_23_april_2021_FR

De Raad van Bestuur van Vastned Retail Belgium heeft besloten om de heer Walta, met ingang vanaf 23 april 2021, definitief te benoemen tot strategische CEO. De heer Walta nam deze functie reeds waar vanaf 1 december 2020 op een ad interim basis. Volledig persbericht: BijlagePersbericht_23_april_2021_NL

WILMINGTON, Del., April 23, 2021 (GLOBE NEWSWIRE) — Ashland Global Holdings Inc. (NYSE: ASH) will issue its second-quarter earnings release at approximately 5 p.m. ET on Wednesday, April 28, 2021. The company’s live webcast with securities analysts and investors will take place at 10 a.m. ET, Thursday, April 29, 2021 and include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website http://investor.ashland.com. Among those participating in the webcast presentation will be:Guillermo Novo, chairman and chief executive officer; Kevin Willis, senior vice president and chief financial officer; and Seth Mrozek, director of investor relations.The webcast and supporting materials will be accessible through the Investor Relations section of...

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) a pan-America (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement under which Knight will acquire the exclusive rights to manufacture, market and sell Exelon® (rivastigmine Patch, Capsules and Solution) in Canada and Latin America (the “Territory”), as well as an exclusive license to use the intellectual property and the Exelon trademark, from Novartis within the Territory. Exelon (rivastigmine) is a prescription product that was first approved in 1997 and is currently registered and sold in approximately 90 countries. Exelon is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease. At closing, Knight will pay USD $168...

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), uma empresa farmacêutica especializada panamericana (ex-EUA), anunciou hoje que celebrou um acordo definitivo pelo qual a Knight adquirirá os direitos exclusivos para fabricar, comercializar e vender Exelon® (adesivo de rivastigmina, cápsulas e solução) no Canadá e na América Latina (o “Território”), assim como uma licença exclusiva para usar a propriedade intelectual e a marca Exelon da Novartis dentro do Território. Exelon (rivastigmina) é um produto de prescrição que foi aprovado pela primeira vez em 1997 e atualmente está registrado e é vendido em aproximadamente 90 países. O Exelon é indicado para o tratamento sintomático da demência leve a moderadamente grave em pessoas com doença de Alzheimer. No fechamento...

MONTREAL, April 23, 2021 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”) una compañía farmacéutica especializada panamericana (ex-EE.UU.), anunció hoy que ha celebrado un acuerdo definitivo en virtud del cual Knight adquirirá el derechos exclusivos para fabricar, comercializar y vender Exelon® (parche de rivastigmina, cápsulas y solución) en Canadá y América Latina (el “Territorio”), así como una licencia exclusiva para usar la propiedad intelectual y la marca comercial Exelon de Novartis dentro del Territorio. Exelon (rivastigmina) es un producto recetado que se aprobó por primera vez en 1997 y actualmente está registrado y es vendido en aproximadamente 90 países. Exelon está indicado para el tratamiento sintomático de la demencia leve a moderadamente grave en personas con la enfermedad...

MONTRÉAL, 23 avr. 2021 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société »), société pharmaceutique spécialisée panaméricaine (ex-ÉU), a annoncé aujourd’hui la conclusion d’une entente définitive par laquelle Knight acquerra les droits exclusifs de fabrication, de commercialisation et de vente d’Exelon® (timbre, capsules et solution de rivastigmine) au Canada et en Amérique latine (le « territoire »), ainsi qu’une licence exclusive d’utilisation de la propriété intellectuelle et de la marque Exelon, de Novartis dans le territoire. Exelon (rivastigmine) est un produit délivré sur ordonnance approuvé pour la première fois en 1997 et présentement homologué et vendu dans quelque 90 pays. Exelon est indiqué pour le traitement symptomatique de la démence légère à modérément sévère parmi les patients...

Not for release to US wire services or distribution in the United States TORONTO, April 23, 2021 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX:XAM, TSX:XAM) (Xanadu or the Company) is pleased to announce the Company has received firm commitments for a placement to eligible professional and sophisticated investors of approximately 163.8 million fully-paid ordinary shares in Xanadu (New Shares) at an issue price of $0.062 each to raise approximately $10.2 million (before costs) (Placement). HighlightsFirm commitments received for a Placement to raise approximately $10.2 million (before costs) Well supported by both domestic and international institutions Strong financial position to deliver Kharmagtai exploration strategy, targeting resource growth and definition of high-grade bornite-rich zones at depth Concurrent with the Placement,...

The meeting of the Supervisory Board of AB Kauno Energija has been held on April 21, 2021. The decision in accordance with Items 1 and 6 of Paragraph 1 of Article 32 of the Law on Companies of the Republic of Lithuania has been made, as follows:1) to accept and propose to the General Meeting of Shareholders of AB Kauno Energija to approve the audited Consolidated Financial Statements of AB Kauno Energija for the year 2020 prepared in accordance with International Financial Reporting Standards as adopted by the European Union, together with a Consolidated Annual Report and an independent auditor’s conclusion;2) to accept and propose to the General Meeting of Shareholders of AB Kauno Energija to allocate the profit of AB Kauno Energija in accordance with the 2020 year profit (loss) allocation project submitted to the General Meeting of...

AB „Kauno energija“ stebėtojų taryba 2021 m. balandžio 21 d. posėdyje, vadovaudamasi Lietuvos Respublikos akcinių bendrovių įstatymo 32 straipsnio 1 dalies 1 ir 6 punktais, nusprendė:pritarti ir siūlyti AB „Kauno energija“ eiliniam visuotiniam akcininkų susirinkimui tvirtinti audituotą AB „Kauno energija“ konsoliduotųjų ir Bendrovės 2020 m. finansinių ataskaitų rinkinį, parengtą pagal Tarptautinius finansinės atskaitomybės standartus, priimtus taikyti Europos Sąjungoje, pateiktą kartu su konsoliduotuoju metiniu pranešimu bei nepriklausomo autoriaus išvada; pritarti ir siūlyti AB „Kauno energija“ eiliniam visuotiniam akcininkų susirinkimui paskirstyti AB „Kauno energija“ pelną pagal eiliniam visuotiniam akcininkų susirinkimui pateiktą 2020 m. pelno (nuostolių) paskirstymo projektą; pritarti AB „Kauno energija“ veiklos strategijos įgyvendinimui...